医学界消化频道|重视便秘型肠易激综合征治疗,期待疗效良好的新药尽早进入医保( 三 )


[9] Chey W D, Lembo A J, Lavins B J, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety[J]. The American Journal of Gastroenterology, 2012, 107(11): 1702-1712.
[10] Rao S, Lembo A J, Shiff S J, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation[J]. The American Journal of Gastroenterology, 2012, 107(11): 1714-24.
[11] Busby R W, Kessler M M, Bartolini W P, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation[J]. Journal of Pharmacology and Experimental Therapeutics, 2013, 344(1): 196-206.
[12] Taylor D C, Abel J L, Bancroft T, et al. Health Care Resource Use and Costs Pre-and Post-Treatment Initiation With Linaclotide: Retrospective Analyses of a US Insured Population[J]. Managed Care (Langhorne, Pa.), 2018, 27(2): 33-40.
[13] Buono J L, Tourkodimitris S, Sarocco P, et al. Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials[J]. American Health & Drug Benefits, 2014, 7(5): 289.
声明:本内容仅针对中国医疗卫生专业人士 , 旨在向且仅向医疗卫生专业人士提供科学信息 , 用于个人学习和参考之用 。 如果您不是医疗卫生专业人士 , 请勿参与或传播 。- End - 【医学界消化频道|重视便秘型肠易激综合征治疗,期待疗效良好的新药尽早进入医保】


推荐阅读